Bioton finally breaks into Russian insulin market

The information was received well by investors, as sales to Russia are expected to substantially drive company growth in 2007. Bioton intends to control 25% of the market, which is currently worth zl.200 million and growing at an annual pace of 10%. This Bioton Wostok contract represents the final move in this direction, as it will now be easier to acquire new clients and partners. The contract was signed as part of central tenders, which encompass 40% of the market in Russia. "Bioton Wostok also participates in regional tenders encompassing the remaining share of the market," said Adam Wilczega, president of Bioton. (Puls Biznesu, pp. 1, 12-13) M.M.